Tudor Moldoveanu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7559610/publications.pdf

Version: 2024-02-01

42 papers 4,925 citations

30 h-index 276875 41 g-index

46 all docs

46 docs citations

46 times ranked 6353 citing authors

#	Article	IF	CITATIONS
1	The BCL-2 Family Reunion. Molecular Cell, 2010, 37, 299-310.	9.7	1,295
2	A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria. Molecular Cell, 2011, 44, 517-531.	9.7	502
3	Many players in BCL-2 family affairs. Trends in Biochemical Sciences, 2014, 39, 101-111.	7.5	352
4	A Ca2+ Switch Aligns the Active Site of Calpain. Cell, 2002, 108, 649-660.	28.9	311
5	The X-Ray Structure of a BAK Homodimer Reveals an Inhibitory Zinc Binding Site. Molecular Cell, 2006, 24, 677-688.	9.7	213
6	BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. Cell, 2016, 165, 421-433.	28.9	197
7	Sequential Engagement of Distinct MLKL Phosphatidylinositol-Binding Sites Executes Necroptosis. Molecular Cell, 2016, 61, 589-601.	9.7	183
8	BID-induced structural changes in BAK promote apoptosis. Nature Structural and Molecular Biology, 2013, 20, 589-597.	8.2	181
9	Discoveries and controversies in <scp>BCL</scp> â€2 proteinâ€mediated apoptosis. FEBS Journal, 2016, 283, 2690-2700.	4.7	176
10	BH3 Domains other than Bim and Bid Can Directly Activate Bax/Bak. Journal of Biological Chemistry, 2011, 286, 491-501.	3 . 4	139
11	Concerted multi-pronged attack by calpastatin to occlude the catalytic cleft of heterodimeric calpains. Nature, 2008, 456, 404-408.	27.8	131
12	Determination of Peptide Substrate Specificity for \hat{l} /4-Calpain by a Peptide Library-based Approach. Journal of Biological Chemistry, 2005, 280, 40632-40641.	3.4	115
13	MLKL Requires the Inositol Phosphate Code to Execute Necroptosis. Molecular Cell, 2018, 70, 936-948.e7.	9.7	111
14	BAX, BAK, and BOK: A Coming of Age for the BCL-2 Family Effector Proteins. Cold Spring Harbor Perspectives in Biology, 2020, 12, a036319.	5 . 5	106
15	Crystal Structures of Calpain–E64 and –Leupeptin Inhibitor Complexes Reveal Mobile Loops Gating the Active Site. Journal of Molecular Biology, 2004, 343, 1313-1326.	4.2	80
16	Calpain silencing by a reversible intrinsic mechanism. Nature Structural and Molecular Biology, 2003, 10, 371-378.	8.2	72
17	Apoptotic Regulation by MCL-1 through Heterodimerization. Journal of Biological Chemistry, 2010, 285, 19615-19624.	3.4	64
18	Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer. Cancer Research, 2017, 77, 6282-6298.	0.9	62

#	Article	IF	CITATIONS
19	Mutations in Calpain 3 Associated with Limb Girdle Muscular Dystrophy: Analysis by Molecular Modeling and by Mutation in m-Calpain. Biophysical Journal, 2001, 80, 2590-2596.	0.5	58
20	Structural Model of the BCL-wâ^BID Peptide Complex and Its Interactions with Phospholipid Micelles,. Biochemistry, 2006, 45, 2250-2256.	2.5	54
21	Calpain Inhibition by α-Ketoamide and Cyclic Hemiacetal Inhibitors Revealed by X-ray Crystallography,. Biochemistry, 2006, 45, 7446-7452.	2.5	52
22	Calpain Activation by Cooperative Ca2+ Binding at Two Non-EF-hand Sites. Journal of Biological Chemistry, 2004, 279, 6106-6114.	3.4	48
23	Insertion Sequence 1 of Muscle-specific Calpain, p94, Acts as an Internal Propeptide. Journal of Biological Chemistry, 2004, 279, 27656-27666.	3.4	48
24	Calpain Mutants with Increased Ca2+ Sensitivity and Implications for the Role of the C2-like Domain. Journal of Biological Chemistry, 2001, 276, 7404-7407.	3.4	45
25	Intrinsic Instability of BOK Enables Membrane Permeabilization in Apoptosis. Cell Reports, 2018, 23, 2083-2094.e6.	6.4	41
26	Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFUÂtumour suppressor. Nature Cell Biology, 2017, 19, 1226-1236.	10.3	38
27	Direct Activation of Human MLKL by a Select Repertoire of Inositol Phosphate Metabolites. Cell Chemical Biology, 2019, 26, 863-877.e7.	5.2	38
28	Structural Basis for UBA-mediated Dimerization of c-Cbl Ubiquitin Ligase. Journal of Biological Chemistry, 2007, 282, 27547-27555.	3.4	37
29	Development of Calpain-specific Inactivators by Screening of Positional Scanning Epoxide Libraries. Journal of Biological Chemistry, 2007, 282, 9600-9611.	3.4	36
30	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 325-339.	9.7	35
31	Ca 2+ -induced structural changes in rat m -calpain revealed by partial proteolysis. BBA - Proteins and Proteomics, 2001, 1545, 245-254.	2.1	25
32	Diversifying selection and functional analysis of interleukin-4 suggests antagonism-driven evolution at receptor-binding interfaces. BMC Evolutionary Biology, 2010, 10, 223.	3.2	19
33	Structural basis of BAK activation in mitochondrial apoptosis initiation. Nature Communications, 2022, 13, 250.	12.8	19
34	Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis. Journal of Visualized Experiments, 2018, , .	0.3	14
35	Protein–protein and protein–lipid interactions of pore-forming BCL-2 family proteins in apoptosis initiation. Biochemical Society Transactions, 2022, , .	3.4	12
36	Metastability, an emerging concept governing BOK-mediated apoptosis initiation. Oncotarget, 2018, 9, 30944-30945.	1.8	5

3

#	ARTICLE	IF	CITATIONS
37	Methods to Probe Conformational Activation and Mitochondrial Activity of Proapoptotic BAK. Methods in Molecular Biology, 2019, 1877, 185-200.	0.9	3
38	Linker Histone H1.2 Directly Activates BAK through the K/RVVKP Motif on the C-Terminal Domain. Biochemistry, 2020, 59, 3332-3346.	2.5	3
39	Uncovering human mixed lineage kinase domain-like activation in necroptosis. Future Medicinal Chemistry, 2019, 11, 2831-2844.	2.3	2
40	A killer metamorphosis: catching BAK in action at the membrane. EMBO Journal, 2021, 40, e109529.	7.8	2
41	Metabolic Activation of CaMKII by Coenzyme A. Molecular Cell, 2013, 52, 468.	9.7	1
42	MP57-03 IDENTIFICATION AND CHARACTERIZATION OF SELECTIVE ANDROGEN RECEPTOR DEGRADERS (SARDS) FOR THE TREATMENT OF ENZALUTAMIDE UNRESPONSIVE AND/OR RESISTANT PROSTATE CANCER. Journal of Urology, 2017, 197, .	0.4	O